Volex (AIM: VLX) upgrades FY2026 revenue to at least $1.22bn as AI data centre demand doubles and board eyes Main Market move
Can inhaled nintedanib improve tolerability and adherence in IPF treatment, according to Avalyn Pharma Inc.?
Read More 5 minute read Pharma Industry News Will payers embrace premium weight loss? Inside the reimbursement risks of next-gen GLP-1s As GLP‑1 weight‑loss drugs climb toward blockbuster status, insurers and payers face tough choices on coverage. Can premium weight‑loss therapies become mainstream? bySrinathDecember 2, 2025